<DOC>
	<DOCNO>NCT00137800</DOCNO>
	<brief_summary>The primary purpose study determine whether drug OSI-774 le toxic potentially good well standard chemotherapy drug , give subject non-small cell lung cancer , 70 year age old .</brief_summary>
	<brief_title>Study OSI-774 ( Tarceva ) Previously Untreated Elderly Lung Cancer Patients</brief_title>
	<detailed_description>Patients receive OSI-774 daily without interruption . There pre-determined number cycle plan dose interruption . For purpose evaluation , toxicity efficacy , four week ( 28 day period ) consider 1 cycle . Patients continue receive OSI-774 develop progressive disease , unacceptable side-effects wish withdraw study . Patients radiographic evaluation every two cycle therapy . After cycle 2 , patient also evaluate FDG-PET scanning . Patients also ask fill Lung Cancer Symptom Scale ( LCSS ) first day cycle . Bloodwork also perform day 1 cycle well end study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age : 70 year age old Stage IV IIIB nonsmall cell lung cancer ( NSCLC ) Measurable tumor ( ) Three week since prior radiation therapy Three week since prior major surgery Must least able walk capable take care oneself although unable carry work activity . Must 50 % waking hour . Life expectancy 8 week Blood test show kidney , liver bone marrow work adequately Completely heal previous oncologic major surgery Prior chemotherapy regimen nonsmall cell lung cancer Prior exposure OSI774 similar treatment trastuzumab , ZD1839 , C225 , etc . Uncontrolled central nervous system metastases Concurrent active cancer Malignancies within past 5 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin Prior chemotherapy malignant disease Difficulty swallow A disease disorder interfere ability digest absorb food A medical condition could make unsafe patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Elderly Cancer Patients</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Stage IIIB IV Non-Small Cell Lung Cancer</keyword>
</DOC>